Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-3914-8171
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.85 billion
Profitability
Miscellaneous
Employees42,535
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions
What is Teva Pharmaceutical Industries' stock symbol?
Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."
How were Teva Pharmaceutical Industries' earnings last quarter?
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) posted its earnings results on Wednesday, August, 7th. The company reported $0.57 EPS for the quarter, topping the Zacks' consensus estimate of $0.55 by $0.02. The business had revenue of $4.34 billion for the quarter, compared to analysts' expectations of $4.25 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.04% and a negative net margin of 21.94%. The business's revenue was down 7.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.78 earnings per share. View Teva Pharmaceutical Industries' Earnings History.
When is Teva Pharmaceutical Industries' next earnings date?
What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?
Teva Pharmaceutical Industries updated its FY19 earnings guidance on Wednesday, August, 7th. The company provided earnings per share guidance of $2.20-2.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.38. The company issued revenue guidance of $17.0-17.4 billion, compared to the consensus revenue estimate of $17.16 billion.
What price target have analysts set for TEVA?
25 brokers have issued 12-month price targets for Teva Pharmaceutical Industries' stock. Their predictions range from $6.00 to $30.00. On average, they anticipate Teva Pharmaceutical Industries' stock price to reach $12.3333 in the next twelve months. This suggests a possible upside of 65.5% from the stock's current price. View Analyst Price Targets for Teva Pharmaceutical Industries.
What is the consensus analysts' recommendation for Teva Pharmaceutical Industries?
25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 5 sell ratings, 14 hold ratings, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teva Pharmaceutical Industries.
What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?
Here are some recent quotes from research analysts about Teva Pharmaceutical Industries stock:
- 1. According to Zacks Investment Research, "Teva is facing significant challenges in the form of accelerated generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business and a massive debt load. Teva expects 2019 to be a tough year followed by return to growth in 2020 based on new launches. Its newest drugs, Austedo and Ajovy could emerge as significant contributors to long-term sales growth. However, despite impressive progress on restructuring activities, signs of stabilization in U.S. generic business and a more stable financial position than before, we believe the company has a long way to go before it gains stability. Resumption of organic growth seems unlikely until 2020. Teva’s shares have underperformed the generic industry this year so far. Estimates have gone down slightly ahead of Q1 earnings release. Teva has a mixed record of earnings surprises." (4/23/2019)
- 2. Maxim Group analysts commented, "Teva reported 3Q18 with revenues of $4.53B vs. $4.55B consensus and beat on the bottom line with non-GAAP EPS of $0.68 vs. $0.55. The beat was driven by positive impacts from the ongoing restructuring strategy with a spend base reduction of $2B YTD compared to 2017 (excluding FX) and on track to reach $3B by YE19." (11/1/2018)
- 3. Cantor Fitzgerald analysts commented, "We rate TEVA 12-month price target of $25. We like Teva’s stock and believe that there is a lot of value to be unlocked, but that it will take time for new leadership to return the business to growth. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25." (9/27/2018)
Has Teva Pharmaceutical Industries been receiving favorable news coverage?
Media stories about TEVA stock have trended somewhat negative on Sunday, InfoTrie reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Teva Pharmaceutical Industries earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Teva Pharmaceutical Industries.
Who are some of Teva Pharmaceutical Industries' key competitors?
Some companies that are related to Teva Pharmaceutical Industries include Shiseido (SSDOY), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TAK), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Mylan (MYL), Array Biopharma (ARRY), Elanco Animal Health (ELAN) and Alnylam Pharmaceuticals (ALNY).
What other stocks do shareholders of Teva Pharmaceutical Industries own?
Who are Teva Pharmaceutical Industries' key executives?
Teva Pharmaceutical Industries' management team includes the folowing people:
- Mr. Kåre Schultz, Pres, CEO & Director (Age 58)
- Mr. Michael McClellan, Exec. VP & CFO (Age 48)
- Mr. Mark Sabag, Exec. VP of Global HR (Age 48)
- Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 61)
- Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 57)
Who are Teva Pharmaceutical Industries' major shareholders?
Teva Pharmaceutical Industries' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.96%), Price T Rowe Associates Inc. MD (0.94%), Northern Trust Corp (0.75%), Camber Capital Management LP (0.64%), Harel Insurance Investments & Financial Services Ltd. (0.53%) and Sumitomo Mitsui Trust Holdings Inc. (0.39%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Iris Beck Codner, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Roberto Mignone, Sol J Barer and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.
Which major investors are selling Teva Pharmaceutical Industries stock?
TEVA stock was sold by a variety of institutional investors in the last quarter, including Polaris Capital Management LLC, Pictet Asset Management Ltd., Pictet Asset Management Ltd., Beck Mack & Oliver LLC, APG Asset Management N.V., Strategic Global Advisors LLC, United Services Automobile Association and AGF Investments Inc.. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.
Which major investors are buying Teva Pharmaceutical Industries stock?
TEVA stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Nuveen Asset Management LLC, Camber Capital Management LP, Marshall Wace LLP, Price T Rowe Associates Inc. MD, Strs Ohio, Voloridge Investment Management LLC and Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Roberto Mignone, Sol J Barer and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.
How do I buy shares of Teva Pharmaceutical Industries?
Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Teva Pharmaceutical Industries' stock price today?
One share of TEVA stock can currently be purchased for approximately $7.45.
How big of a company is Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries has a market capitalization of $8.13 billion and generates $18.85 billion in revenue each year. The company earns $-2,150,000,000.00 in net income (profit) each year or $2.80 on an earnings per share basis. Teva Pharmaceutical Industries employs 42,535 workers across the globe.View Additional Information About Teva Pharmaceutical Industries.
What is Teva Pharmaceutical Industries' official website?
How can I contact Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]
MarketBeat Community Rating for Teva Pharmaceutical Industries (NYSE TEVA)
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
